GlassScriptPhysician profile
Sudhir Prasada
NPI 1710971585
$4,850.17
in general payments reported to CMS, 2019-2025
42 companies · $917 in 2025
The $917 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $281 · 2021: $389 · 2022: $404 · 2023: $637 · 2024: $1,399 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Travel and Lodging: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.70 |
| Travel and Lodging | $537.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,177.49 | 2023-2025 | Impella |
| Abbott Laboratories | $472.78 | 2019-2025 | Diamondback Peripheral, Perclose Prostyle, Supera |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $375.58 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $364.82 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $278.85 | 2019-2024 | Farxiga, Brilinta |
| Terumo Medical Corporation | $228.85 | 2019 | |
| Pfizer INC. | $222.48 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.99 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $182.02 | 2024-2025 | Avvigo Guidance System, Opticross 6, General - Therapies |
| Janssen Pharmaceuticals, INC | $145.84 | 2019-2021 | |
| Irhythm Technologies, INC. | $139.02 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $135.54 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.43 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $127.66 | 2021-2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $95.23 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.63 | 2022-2025 | |
| Shockwave Medical, INC | $65.16 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $64.68 | 2021-2025 | Ffrangio |
| Baxter Healthcare | $48.90 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $38.11 | 2019 | |
| Recor Medical INC | $25.60 | 2024 | Paradise Renal Denervation System |
| Amarin Pharma, INC. | $25.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.43 | 2021-2022 | |
| Novo Nordisk INC | $24.42 | 2025 | Wegovy |
| Bard Peripheral Vascular, INC. | $22.55 | 2023 | Lutonix Drug Coated Balloon |
| Esperion Therapeutics, INC. | $22.31 | 2023 | Nexletol |
| Cordis US Corp. | $19.55 | 2025 | Mynx Control |
| Philips North America LLC | $18.22 | 2025 | Coronary Other |
| Preventice Services, LLC | $17.87 | 2021 | |
| Teleflex LLC | $14.28 | 2024 | Supercross |
| Inari Medical, INC. | $13.43 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ge Healthcare | $12.92 | 2021 | |
| Biotronik INC. | $12.89 | 2023 | Orsiro Mission |
| Medtronic Vascular, INC. | $12.16 | 2019 | |
| Flowphysix INC | $11.19 | 2025 | Flowrunner |
| Cardiovascular Systems INC. | $8.80 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhir Prasada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.